



Professor David Nutt

DM, FRCP, FRCPSYCH, FSB, FMEDSCI
CHIEF RESEARCH OFFICER –
AWAKN LIFE SCIENCES

Prof. Nutt is Chief Research Officer at Awakn Life Sciences, a biotechnology company researching, developing, and delivering psychedelic therapeutics to treat addiction.

He is a psychiatrist and the Edmund J. Safra Professor of Neuropsychopharmacology in the Division of Brain Science, Dept of Medicine, Imperial College London, where he uses a range of brain imaging techniques to explore the causes of addiction and other psychiatric disorders and to search for new treatments.

He is also director of the Neuropsychopharmacology Unit in the Division of Brain Sciences. He completed his medical training at Guy's Hospital London in neurology to magnetic resonance cholangiopancreatography (MRCP), before training in psychiatry in Oxford and continuing there as a lecturer and a Wellcome Senior Fellow in Psychiatry. In 1988 he set up the Psychopharmacology Unit in Bristol University, an interdisciplinary research group spanning the departments of Psychiatry and Pharmacology before moving to Imperial College London in December 2008, where he leads a similar group with a particular focus on brain imaging.

Prof. Nutt is President of the European Brain Council and Founding Chair of Drug Science. Previously, he was President of the European College of Neuropsychopharmacology, the British Neuroscience Association and the British Association of Psychopharmacology. In addition, he is a Fellow of the Royal Colleges of Physicians and of Psychiatrists and a Fellow of the Academy of Medical Sciences. He has published over 500 original research papers, a similar number of reviews and books chapters, eight government reports on drugs and 34 books.

He broadcasts widely to the general public both on radio and

television. In 2010, The Times Eureka science magazine voted him one of the 100 most important figures in British Science and in 2013 he was awarded the John Maddox Prize from Nature/Sense about Science for standing up for science.

Relevant publications

- Rolles S, Nutt DJ, Schlag AK (2021) **Some Contributions on How to Formulate Drug Policies and Provide Evidence-Based Regulation**, American Journal of Bioethics, Vol: 21, Pages: 28-31, ISSN: 1526-5161
- Nutt D, Carhart-Harris R (2021) **The Current Status of Psychedelics in Psychiatry**, JAMA PSYCHIATRY, Vol: 78, Pages: 121-122, ISSN: 2168-622X
- Andersen KAA, Carhart-Harris R, Nutt DJ, Erritzoe Det al., (2020) **Therapeutic effects of classic serotonergic psychedelics: A systematic review of modern-era clinical studies**, ACTA PSYCHIATRICA SCANDINAVICA, Vol: 143, Pages: 101-118, ISSN: 0001-690X
- Nutt D, Nestor L, Suckling J, et al., (2020) **Disturbances across whole brain networks during reward anticipation in an abstinent addiction population.**, NeuroImage: Clinical, Vol: 27, Pages: 1-10, ISSN: 2213-1582
- Nutt D, Erritzoe D, Carhart-Harris R, (2020) **Psychedelic Psychiatry's Brave New World**, CELL, Vol: 181, Pages: 24-28, ISSN: 0092-8674
- Nutt D, (2020) **New psychoactive substances: Pharmacology influencing UK practice, policy and the law**, BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, Vol: 86, Pages: 445-451, ISSN: 0306